DiaGen Ai Collaborates with Structural Genomics Consortium at Chapel Hill

DiaGen AI Inc. has entered into a research collaboration with the Structural Genomics Consortium at UNC Chapel Hill. The partnership aims to develop DiaGen’s AI-generated peptides to target KRAS-G12D, a key cancer-causing mutant, offering new therapeutic strategies. This collaboration signifies a promising step forward in cancer treatment and peptide discovery. Learn more here.